|Bid||101.00 x 900|
|Ask||102.61 x 900|
|Day's range||101.65 - 105.07|
|52-week range||97.86 - 142.64|
|Beta (5Y monthly)||1.32|
|PE ratio (TTM)||32.11|
|Earnings date||31 Jan 2022 - 04 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||159.46|
Nevro's (NVRO) receipt of the FDA's approval for expanded labeling of its Senza SCS System is expected to cater to underserved patients.
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
Catalent's (CTLT) Xpress Pharmaceutics service offers a quicker alternative to the traditional clinical development model, lowering the time needed to complete clinical studies.